Will Tesla Stock Go Up In 2026?
EV giant Tesla (NASDAQ:TSLA) has, somewhat surprisingly, undershot the broader…
Sell
37
MTVA Quote, Financials, Valuation and Earnings
Last price:
$8.43
Seasonality move
:
-5.96%
Day range:
$8.49 - $9.68
52-week range:
$6.05 - $30.25
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
37.35x
Volume:
81.5K
Avg. volume:
371.3K
1-year change:
-63.28%
Market cap:
$236.5M
Revenue:
--
EPS (TTM):
-$11.34
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
MTVA
MetaVia, Inc.
|
-- | -$0.65 | -- | -69.19% | $132.00 |
|
NBY
NovaBay Pharmaceuticals, Inc.
|
$3M | -$0.88 | 14.03% | -95.43% | $0.85 |
|
NNVC
NanoViricides, Inc.
|
-- | -$0.20 | -- | -26.67% | $7.00 |
|
OGEN
Oragenics, Inc.
|
-- | -- | -- | -- | $2.00 |
|
PTN
Palatin Technologies
|
-- | -$0.17 | -- | -67.93% | -- |
|
TOVX
Theriva Biologics, Inc.
|
-- | -$0.38 | -- | -94.42% | $7.00 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
MTVA
MetaVia, Inc.
|
$9.31 | $132.00 | $236.5M | -- | $0.00 | 0% | -- |
|
NBY
NovaBay Pharmaceuticals, Inc.
|
$2.80 | $0.85 | $352.8M | 4.70x | $0.80 | 0% | 5.44x |
|
NNVC
NanoViricides, Inc.
|
$1.25 | $7.00 | $22.5M | -- | $0.00 | 0% | -- |
|
OGEN
Oragenics, Inc.
|
$0.91 | $2.00 | $752.1K | -- | $0.00 | 0% | 0.53x |
|
PTN
Palatin Technologies
|
$0.09 | -- | $2.4M | -- | $0.00 | 0% | -- |
|
TOVX
Theriva Biologics, Inc.
|
$0.22 | $7.00 | $7.3M | -- | $0.00 | 0% | 0.33x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
MTVA
MetaVia, Inc.
|
1.23% | 1.858 | 0.03% | 1.69x |
|
NBY
NovaBay Pharmaceuticals, Inc.
|
37.25% | 2.113 | 8.08% | 1.85x |
|
NNVC
NanoViricides, Inc.
|
-- | 0.464 | -- | 0.95x |
|
OGEN
Oragenics, Inc.
|
3.86% | -0.075 | 36.62% | 3.97x |
|
PTN
Palatin Technologies
|
-- | 1.358 | -- | -- |
|
TOVX
Theriva Biologics, Inc.
|
29.07% | -3.365 | 66.16% | 0.68x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
MTVA
MetaVia, Inc.
|
-$5K | -$3.5M | -193.95% | -196.71% | -- | -$3M |
|
NBY
NovaBay Pharmaceuticals, Inc.
|
$42K | -$1.2M | -208.55% | -306.03% | -224.38% | -$1.8M |
|
NNVC
NanoViricides, Inc.
|
-$132.8K | -$1.8M | -92.29% | -92.29% | -- | -$1.7M |
|
OGEN
Oragenics, Inc.
|
-- | -$3.1M | -311.49% | -509.23% | -- | -$3M |
|
PTN
Palatin Technologies
|
-- | -- | -- | -- | -- | -- |
|
TOVX
Theriva Biologics, Inc.
|
-$28K | -$4.4M | -148.18% | -171.04% | -- | -$4.3M |
MetaVia, Inc. vs. Competitors
-
Which has Higher Returns MTVA or NBY?
NovaBay Pharmaceuticals, Inc. has a net margin of -- compared to MetaVia, Inc.'s net margin of -255.85%. MetaVia, Inc.'s return on equity of -196.71% beat NovaBay Pharmaceuticals, Inc.'s return on equity of -306.03%.
Company Gross Margin Earnings Per Share Invested Capital MTVAMetaVia, Inc.-- -$1.52 $6.4M NBYNovaBay Pharmaceuticals, Inc.8.06% -$0.22 $2.6M -
What do Analysts Say About MTVA or NBY?
MetaVia, Inc. has a consensus price target of $132.00, signalling upside risk potential of 1317.83%. On the other hand NovaBay Pharmaceuticals, Inc. has an analysts' consensus of $0.85 which suggests that it could fall by -69.64%. Given that MetaVia, Inc. has higher upside potential than NovaBay Pharmaceuticals, Inc., analysts believe MetaVia, Inc. is more attractive than NovaBay Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings MTVAMetaVia, Inc.2 0 0 NBYNovaBay Pharmaceuticals, Inc.1 0 0 -
Is MTVA or NBY More Risky?
MetaVia, Inc. has a beta of 0.286, which suggesting that the stock is 71.44% less volatile than S&P 500. In comparison NovaBay Pharmaceuticals, Inc. has a beta of 0.569, suggesting its less volatile than the S&P 500 by 43.103%.
-
Which is a Better Dividend Stock MTVA or NBY?
MetaVia, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.80 per share. MetaVia, Inc. pays -- of its earnings as a dividend. NovaBay Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios MTVA or NBY?
MetaVia, Inc. quarterly revenues are --, which are smaller than NovaBay Pharmaceuticals, Inc. quarterly revenues of $521K. MetaVia, Inc.'s net income of -$3.4M is lower than NovaBay Pharmaceuticals, Inc.'s net income of -$1.3M. Notably, MetaVia, Inc.'s price-to-earnings ratio is -- while NovaBay Pharmaceuticals, Inc.'s PE ratio is 4.70x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for MetaVia, Inc. is -- versus 5.44x for NovaBay Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income MTVAMetaVia, Inc.-- -- -- -$3.4M NBYNovaBay Pharmaceuticals, Inc.5.44x 4.70x $521K -$1.3M
-
Which has Higher Returns MTVA or NNVC?
NanoViricides, Inc. has a net margin of -- compared to MetaVia, Inc.'s net margin of --. MetaVia, Inc.'s return on equity of -196.71% beat NanoViricides, Inc.'s return on equity of -92.29%.
Company Gross Margin Earnings Per Share Invested Capital MTVAMetaVia, Inc.-- -$1.52 $6.4M NNVCNanoViricides, Inc.-- -$0.10 $7.2M -
What do Analysts Say About MTVA or NNVC?
MetaVia, Inc. has a consensus price target of $132.00, signalling upside risk potential of 1317.83%. On the other hand NanoViricides, Inc. has an analysts' consensus of $7.00 which suggests that it could grow by 460%. Given that MetaVia, Inc. has higher upside potential than NanoViricides, Inc., analysts believe MetaVia, Inc. is more attractive than NanoViricides, Inc..
Company Buy Ratings Hold Ratings Sell Ratings MTVAMetaVia, Inc.2 0 0 NNVCNanoViricides, Inc.0 0 0 -
Is MTVA or NNVC More Risky?
MetaVia, Inc. has a beta of 0.286, which suggesting that the stock is 71.44% less volatile than S&P 500. In comparison NanoViricides, Inc. has a beta of 1.158, suggesting its more volatile than the S&P 500 by 15.816%.
-
Which is a Better Dividend Stock MTVA or NNVC?
MetaVia, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NanoViricides, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. MetaVia, Inc. pays -- of its earnings as a dividend. NanoViricides, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios MTVA or NNVC?
MetaVia, Inc. quarterly revenues are --, which are smaller than NanoViricides, Inc. quarterly revenues of --. MetaVia, Inc.'s net income of -$3.4M is lower than NanoViricides, Inc.'s net income of -$1.8M. Notably, MetaVia, Inc.'s price-to-earnings ratio is -- while NanoViricides, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for MetaVia, Inc. is -- versus -- for NanoViricides, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income MTVAMetaVia, Inc.-- -- -- -$3.4M NNVCNanoViricides, Inc.-- -- -- -$1.8M
-
Which has Higher Returns MTVA or OGEN?
Oragenics, Inc. has a net margin of -- compared to MetaVia, Inc.'s net margin of --. MetaVia, Inc.'s return on equity of -196.71% beat Oragenics, Inc.'s return on equity of -509.23%.
Company Gross Margin Earnings Per Share Invested Capital MTVAMetaVia, Inc.-- -$1.52 $6.4M OGENOragenics, Inc.-- -$1.96 $10.2M -
What do Analysts Say About MTVA or OGEN?
MetaVia, Inc. has a consensus price target of $132.00, signalling upside risk potential of 1317.83%. On the other hand Oragenics, Inc. has an analysts' consensus of $2.00 which suggests that it could grow by 118.82%. Given that MetaVia, Inc. has higher upside potential than Oragenics, Inc., analysts believe MetaVia, Inc. is more attractive than Oragenics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings MTVAMetaVia, Inc.2 0 0 OGENOragenics, Inc.1 0 0 -
Is MTVA or OGEN More Risky?
MetaVia, Inc. has a beta of 0.286, which suggesting that the stock is 71.44% less volatile than S&P 500. In comparison Oragenics, Inc. has a beta of 0.922, suggesting its less volatile than the S&P 500 by 7.781%.
-
Which is a Better Dividend Stock MTVA or OGEN?
MetaVia, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Oragenics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. MetaVia, Inc. pays -- of its earnings as a dividend. Oragenics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios MTVA or OGEN?
MetaVia, Inc. quarterly revenues are --, which are smaller than Oragenics, Inc. quarterly revenues of --. MetaVia, Inc.'s net income of -$3.4M is lower than Oragenics, Inc.'s net income of -$3.1M. Notably, MetaVia, Inc.'s price-to-earnings ratio is -- while Oragenics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for MetaVia, Inc. is -- versus 0.53x for Oragenics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income MTVAMetaVia, Inc.-- -- -- -$3.4M OGENOragenics, Inc.0.53x -- -- -$3.1M
-
Which has Higher Returns MTVA or PTN?
Palatin Technologies has a net margin of -- compared to MetaVia, Inc.'s net margin of --. MetaVia, Inc.'s return on equity of -196.71% beat Palatin Technologies's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital MTVAMetaVia, Inc.-- -$1.52 $6.4M PTNPalatin Technologies-- -- -- -
What do Analysts Say About MTVA or PTN?
MetaVia, Inc. has a consensus price target of $132.00, signalling upside risk potential of 1317.83%. On the other hand Palatin Technologies has an analysts' consensus of -- which suggests that it could grow by 7338.9%. Given that Palatin Technologies has higher upside potential than MetaVia, Inc., analysts believe Palatin Technologies is more attractive than MetaVia, Inc..
Company Buy Ratings Hold Ratings Sell Ratings MTVAMetaVia, Inc.2 0 0 PTNPalatin Technologies0 0 0 -
Is MTVA or PTN More Risky?
MetaVia, Inc. has a beta of 0.286, which suggesting that the stock is 71.44% less volatile than S&P 500. In comparison Palatin Technologies has a beta of 0.939, suggesting its less volatile than the S&P 500 by 6.103%.
-
Which is a Better Dividend Stock MTVA or PTN?
MetaVia, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Palatin Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. MetaVia, Inc. pays -- of its earnings as a dividend. Palatin Technologies pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios MTVA or PTN?
MetaVia, Inc. quarterly revenues are --, which are larger than Palatin Technologies quarterly revenues of --. MetaVia, Inc.'s net income of -$3.4M is higher than Palatin Technologies's net income of --. Notably, MetaVia, Inc.'s price-to-earnings ratio is -- while Palatin Technologies's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for MetaVia, Inc. is -- versus -- for Palatin Technologies. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income MTVAMetaVia, Inc.-- -- -- -$3.4M PTNPalatin Technologies-- -- -- --
-
Which has Higher Returns MTVA or TOVX?
Theriva Biologics, Inc. has a net margin of -- compared to MetaVia, Inc.'s net margin of --. MetaVia, Inc.'s return on equity of -196.71% beat Theriva Biologics, Inc.'s return on equity of -171.04%.
Company Gross Margin Earnings Per Share Invested Capital MTVAMetaVia, Inc.-- -$1.52 $6.4M TOVXTheriva Biologics, Inc.-- -$0.45 $9.5M -
What do Analysts Say About MTVA or TOVX?
MetaVia, Inc. has a consensus price target of $132.00, signalling upside risk potential of 1317.83%. On the other hand Theriva Biologics, Inc. has an analysts' consensus of $7.00 which suggests that it could grow by 3121.35%. Given that Theriva Biologics, Inc. has higher upside potential than MetaVia, Inc., analysts believe Theriva Biologics, Inc. is more attractive than MetaVia, Inc..
Company Buy Ratings Hold Ratings Sell Ratings MTVAMetaVia, Inc.2 0 0 TOVXTheriva Biologics, Inc.1 1 0 -
Is MTVA or TOVX More Risky?
MetaVia, Inc. has a beta of 0.286, which suggesting that the stock is 71.44% less volatile than S&P 500. In comparison Theriva Biologics, Inc. has a beta of 0.342, suggesting its less volatile than the S&P 500 by 65.818%.
-
Which is a Better Dividend Stock MTVA or TOVX?
MetaVia, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Theriva Biologics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. MetaVia, Inc. pays -- of its earnings as a dividend. Theriva Biologics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios MTVA or TOVX?
MetaVia, Inc. quarterly revenues are --, which are smaller than Theriva Biologics, Inc. quarterly revenues of --. MetaVia, Inc.'s net income of -$3.4M is higher than Theriva Biologics, Inc.'s net income of -$4.4M. Notably, MetaVia, Inc.'s price-to-earnings ratio is -- while Theriva Biologics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for MetaVia, Inc. is -- versus 0.33x for Theriva Biologics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income MTVAMetaVia, Inc.-- -- -- -$3.4M TOVXTheriva Biologics, Inc.0.33x -- -- -$4.4M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
What Are the Best AI Power Stocks?
As the construction of AI infrastructure accelerates, the gap between…
Is IONQ The Best Quantum Stock to Buy?
Riding a wave of investor enthusiasm for the technology, quantum…
Stock Ideas
Sell
47
Is NVDA Stock a Buy?
Market Cap: $4.3T
P/E Ratio: 60x
Buy
58
Is AAPL Stock a Buy?
Market Cap: $4.1T
P/E Ratio: 37x
Buy
73
Is GOOG Stock a Buy?
Market Cap: $3.7T
P/E Ratio: 39x
Alerts
Buy
80
FEIM alert for Dec 15
Frequency Electronics, Inc. [FEIM] is down 4.13% over the past day.
Buy
57
MOD alert for Dec 15
Modine Manufacturing Co. [MOD] is up 2.57% over the past day.
Sell
42
OKLO alert for Dec 15
Oklo, Inc. [OKLO] is down 4.39% over the past day.
